Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
The RAINIER study continues to enroll patients across additional dose levels. Mipletamig's design leverages Aptevo's ADAPTIR (TM) platform to deliver targeted T-cell engagement with the goal of ...
Findings showed the hazard ratio for OS compared with busulfan was 0.67 in all randomized patients. The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback